Equities

Lumibird SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Lumibird SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)23.30
  • Today's Change1.10 / 4.95%
  • Shares traded36.02k
  • 1 Year change+201.81%
  • Beta0.7929
Data delayed at least 15 minutes, as of Feb 13 2026 16:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

LUMIBIRD SA is a French based company involved in the laser technology. The Company designs, manufactures and distributes high-performance lasers for scientific (research laboratories and universities), industrial (production, defense/space, Lidar sensors), Transport mapping, clean energy, and medical (ophthalmology) uses. The Company products are solid-state lasers, laser diode and components, Fiber lasers and fiber amplifiers, High power fiber lasers. The Company founded in 1997, and it has 15 subsidiaries.

  • Revenue in EUR (TTM)215.95m
  • Net income in EUR10.73m
  • Incorporated1974
  • Employees1.07k
  • Location
    Lumibird SA2 rue du Paul SabatierLANNION 22300FranceFRA
  • Phone+33 169291700
  • Fax+33 169291729
  • Websitehttps://www.lumibird.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Medistim ASA59.31m12.63m313.93m154.0024.788.4320.955.297.797.7936.5622.911.250.76799.674,341,637.0026.7221.9833.0927.1981.2178.6621.3020.322.03--0.048485.046.889.120.00878.1112.5316.89
CellaVision AB71.67m14.46m345.51m236.0023.904.1219.024.826.426.4231.8237.210.72012.026.80--14.5214.7116.2216.9668.5068.3820.1719.852.9725.880.028141.974.949.998.7811.3420.7629.67
COLTENE Holding AG264.20m15.71m360.73m1.18k22.963.6315.601.372.402.4040.2215.131.311.346.40204,684.507.8010.5914.2618.4366.1162.195.957.640.70437.620.360685.663.06-1.7971.310.4306-15.4510.76
IVF Hartmann Holding AG175.01m20.88m381.96m309.0018.312.3914.382.187.927.9266.3960.570.89643.287.88526,221.1010.697.9012.919.6855.7154.0611.939.133.79--0.004248.547.332.8534.0210.78-28.9419.92
Ion Beam Applications SA596.63m17.00m466.95m2.10k27.163.8015.840.78270.56770.567720.174.060.97562.733.28281,693.602.781.5012.034.6431.2134.392.852.150.62097.410.363170.816.7512.01201.573.997.6925.86
Revenio Group Oyj109.70m17.40m496.27m247.0028.444.3122.764.520.6540.6544.124.310.75153.057.26444,129.6011.9214.0014.2317.4070.9270.9515.8619.381.639.660.0969--5.9712.43-5.935.4222.19--
Lumibird SA215.95m10.73m523.48m1.07k48.802.6217.202.420.47750.47759.618.900.50770.95934.42202,198.502.522.513.113.1763.8961.894.974.901.643.160.45830.001.7513.34-20.08-8.3815.27--
medmix AG513.78m-6.37m528.07m2.67k--1.129.881.03-0.1696-0.169611.6010.390.47073.565.86174,403.90-0.49271.27-0.61991.5534.5235.24-1.052.651.101.870.4268140.79-0.55492.84-2,566.67--6.02--
RaySearch Laboratories AB (publ)126.94m21.51m539.22m458.0027.896.4511.014.256.656.6539.2528.740.65846.252.932,935,074.0011.165.2616.217.7792.4291.0116.949.701.6664.920.286152.3812.7715.5811.93--0.2213--
Advanced Medical Solutions Group plc253.36m10.49m548.00m1.50k52.051.8615.682.160.04170.04171.011.170.57582.095.57137,690.002.385.092.635.5252.1955.064.1411.151.553.880.242833.4740.6611.64-55.35-17.818.3610.90
Xvivo Perfusion AB76.69m2.38m550.58m198.00232.322.7661.147.180.79680.796825.7667.100.340.89396.134,101,844.001.053.281.123.5273.8173.863.1010.873.681.830.05570.00-1.2535.19-85.39------
Synektik SA125.16m22.47m599.52m203.0026.6811.3323.684.7911.099.2061.8026.121.2211.183.60--21.9620.1136.1032.6734.9831.4017.9513.601.4142.090.153--9.1640.2951.5870.0228.82--
Arjo AB (publ)1.04bn31.54m648.00m6.94k22.020.98624.810.62381.231.2340.3927.380.7044.926.221,584,702.002.143.262.914.8042.5943.423.044.780.84944.190.417948.74-2.593.92-32.93-8.68--2.25
Gerresheimer AG2.25bn23.35m687.00m13.54k29.420.49012.460.30530.6760.67665.1540.590.54553.737.85185,328.900.63413.300.87164.6826.8930.041.165.840.52142.080.602241.292.287.90-5.526.3217.58-49.35
Paul Hartmann AG2.43bn81.51m782.36m10.09k9.540.66354.060.322422.9522.95682.93330.051.161.975.54240,745.704.124.215.455.7959.5657.303.563.351.1114.110.246537.952.321.95281.5813.2310.082.71
Data as of Feb 13 2026. Currency figures normalised to Lumibird SA's reporting currency: Euro EUR

Institutional shareholders

14.61%Per cent of shares held by top holders
HolderShares% Held
Amiral Gestion SAas of 01 Mar 2025720.50k3.21%
Lazard Fr�res Gestion SASas of 31 Dec 2025499.20k2.22%
Herald Investment Management Ltd.as of 31 Dec 2024438.95k1.95%
AXA Investment Managers (Paris) SAas of 30 Jan 2026305.21k1.36%
CPR Asset Management SAas of 31 Dec 2025300.28k1.34%
Cr�dit Mutuel Asset Management SAas of 30 Oct 2025250.00k1.11%
DNCA Finance SAas of 31 Mar 2025241.32k1.07%
Montpensier Arbevel SASas of 31 Dec 2025190.26k0.85%
Renta 4 Gestora SGIIC SAas of 31 Dec 2025189.00k0.84%
Financi�re Tiepolo SASas of 31 Dec 2024146.93k0.65%
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.